Till startsida
University of Gothenburg
Sitemap
To content Read more about how we use cookies on gu.se

Group Jonas Nilsson

Research Summary

We try to identify new means to treat cancer based on our previous research on the oncogenic transcription factor c-Myc. This research has pointed on potential targets for anti-cancer drugs including kinases, epigenetic readers and metabolic enzymes.
Recently the group's activities has shifted into translating the knowledge gained from the Myc research into melanoma. Myc is overexpressed in melanoma so therefore its expression is not an optimal biomarker to define which of our previously identified targets would be viable in melanoma. Our new research therefore seek to identify biomarkers of response to new targeted therapies. We are also making personalized animal models, so called PDX models or Avatar mice. These are used to test drugs as well as further humanization for use in immune oncology research.
The research has generated the framework of starting the Sahlgrenska Translational Melanoma Group (SATMEG), consisting of basic researchers and clinical investigators working together to devise new therapies against melanoma. Read more about SATMEG activities here:

Sahlgrenska Translational Melanoma Group (SATMEG)

Group Members at SCC

Lead:
Jonas Nilsson, PhD, Group leader at Sahlgrenska Cancer Center and Professor of Experimental Cancer Surgery
Phone: +46 (0)31 786 6768
E-mail: jonas.a.nilsson@surgery.gu.se

Senior Research Fellows:
Lisa Nilsson, PhD, Senior staff scientist
Lars Ny, MD/PhD, Associate professor, oncologist
Berglind Einarsdottir, PhD, Postdoctoral fellow
Paul-Steffen Kuhn, PhD, Postdoctoral fellow
Larissa Rizzo, PhD, Postdoctoral fellow

Post-graduate students:
Henrik Jespersen, MD, Resident in Oncology, PhD student
Elin Söderberg, MSc, PhD student
Valerio Belgrano, MD, PhD student

Technical staff:
Sofia Stenqvist, animal technician

Affiliated members:
Sahlgrenska Translational Melanoma Group (SATMEG)

Selected Publications

  1. Jespersen H, Lindberg MF, Donia M, Söderberg EMV, Andersen R, Keller U, Ny L, Svane IM, Nilsson LM, Nilsson JA. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nature Communications, 8:707, 2017
  2. Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TT, Chaudhary N, Riely GJ, Li BT, Scott K, Cechhi F, Stierner U, Chadalavada K, de Stanchina E, Schwartz S, Hembrough T, Nanjangud G, Berger MF, Nilsson J, Lowe SW, Reis-Filho JS, Rosen N, Lito P. An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. Nature Med, 23:929-937, 2017
  3. Donia M, Harbst K, Van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir S, Ellebaek E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, Svane IM. Acquired immune resistance follows complete tumor regression without loss of target antigens or IFN-γ signaling. Cancer Res, 2017
  4. Nilsson LM, Green LC, Muralidharan SV, Demir D, Welin M, Bhadury J, Logan D, Walse B, Nilsson JA (2016) Cancer differentiation agent hexamethylene bisacetamide was likely the first BET bromodomain inhibitor in clinical trials. Cancer Res, 76:2376-83, 2016.
  5. Muralidharan SV, Bhadury J, Nilsson LM, Green LC, McLure KG and Nilsson JA. BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells. Oncogene, 35:4689-4697, 2016
  6. Panda S, Nilsson JA and Gekara NO. Deubiquitinase MYSM1 regulates innate immunity through inactivation of TRAF3 and TRAF6 complexes. (2015) Immunity 43:647-659.
  7. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. 
Fredriksson NJ, Ny L, Nilsson JA, Larsson E. 
Nat Genet. 2014

  8. Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions.
Einarsdottir BO, Bagge RO, Bhadury J, Jespersen H, Mattsson J, Nilsson LM, Truvé K, López MD, Naredi P, Nilsson O, Stierner U, Ny L, Nilsson JA. 
Oncotarget 2014:5(20):9609-18.

  9. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma.
Bhadury J, Nilsson LM, Muralidharan SV, Green LC, Li Z, Gesner EM, Hansen HC, Keller UB, McLure KG, Nilsson JA. 
Proc Natl Acad Sci U.S.A. 2014:111(26):E2721-30.
  10. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.
Gad Helge, Koolmeister Tobias, Jemth Ann-Sofie, Eshtad Saeed, Jacques Sylvain A, Ström Cecilia E, Svensson Linda M, Schultz Niklas, Lundbäck Thomas, Einarsdottir Berglind Osk, Saleh Aljona, Göktürk Camilla, Baranczewski Pawel, Svensson Richard, Berntsson Ronnie P-A, Gustafsson Robert, Strömberg Kia, Sanjiv Kumar, Jacques-Cordonnier Marie-Caroline, Desroses Matthieu, Gustavsson Anna-Lena, Olofsson Roger, et al [ Nilsson JA Nr. 53 ] Helleday Thomas. 
Nature 2014:508(7495):215-21.

 

PubMed

 

Page Manager: Ulrika Lantz Carlsson|Last update: 4/18/2018
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?